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Background. Cytomegalovirus (CMV) disease remains an important problem in solid-organ transplant
recipients, with the greatest risk among donor CMV-seropositive, recipient-seronegative (D+/R−) patients. CMV-
speciﬁc cell-mediated immunity may be able to predict which patients will develop CMV disease.
Methods. We prospectively included D+/R− patients who received antiviral prophylaxis. We used the Quanti-
feron-CMV assay to measure interferon-γ levels following in vitro stimulation with CMV antigens. The test was
performed at the end of prophylaxis and 1 and 2 months later. The primary outcome was the incidence of CMV
disease at 12 months after transplant. We calculated positive and negative predictive values of the assay for protec-
tion from CMV disease.
Results. Overall, 28 of 127 (22%) patients developed CMV disease. Of 124 evaluable patients, 31 (25%) had a
positive result, 81 (65.3%) had a negative result, and 12 (9.7%) had an indeterminate result (negative mitogen and
CMV antigen) with the Quantiferon-CMV assay. At 12 months, patients with a positive result had a subsequent
lower incidence of CMV disease than patients with a negative and an indeterminate result (6.4% vs 22.2% vs
58.3%, respectively; P < .001). Positive and negative predictive values of the assay for protection from CMV
disease were 0.90 (95% conﬁdence interval [CI], .74–.98) and 0.27 (95% CI, .18–.37), respectively.
Conclusions. This assay may be useful to predict if patients are at low, intermediate, or high risk for the
development of subsequent CMV disease after prophylaxis.
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Cytomegalovirus (CMV) is the most common viral infection
after solid-organ transplantation (SOT) and is associated with
signiﬁcant morbidity [1, 2]. CMV disease commonly presents
as a viral syndrome with fever, malaise, and leukopenia. If left
untreated, it can progress to severe tissue invasive disease. The
SOT recipients at greatest risk for CMV disease are those who
are seronegative recipients of organs from seropositive donors
(D+/R−), representing 15%–25% of the transplant population [1].
Antiviral agents have proven to be useful in the prevention of
CMV disease in SOT recipients, including the high-risk D+/
R− patients [3]. Upon completion of prophylaxis, however,
CMV disease occurs in 25%–35% of D+/R− SOT recipients
within the ﬁrst year after transplant [4, 5]. This is termed
“late-onset” CMV disease and continues to be a signiﬁcant
problem in high-risk transplant recipients [6].
Accurate methods to predict the development of CMV
disease following the completion of prophylaxis would have
signiﬁcant clinical beneﬁt. Routinely available diagnostic tests
are not reliable for predicting the risk of CMV disease in this
setting. CMV RNA testing after prophylaxis in D+/R− patients
has been shown to have poor predictive value for subsequent
CMV disease [7, 8]. CMV serology testing posttransplant was
also shown to be only of marginal use in predicting the risk of
late-onset disease [9]. Cell-mediated immunity is known to be
more important than humoral immunity in controlling CMV
infection [10]. CMV infection elicits a strong virus-speciﬁc
CD4+ and CD8+ T-cell response. Therefore, measuring an in-
dividual’s cell-mediated immunity response to CMV may be a
useful predictor of the risk of CMV infection or disease after
prophylaxis [11–13]. However, many assays for cell-mediated
immunity require laboratory expertise and specialized technol-
ogy, which may not be widely available and often lack stand-
ardization [2].
The Quantiferon-CMV assay measures the interferon
(IFN)–γ responses to a range of T-cell epitopes of CMV pro-
teins including pp65, pp50, the glycoprotein gB, and the im-
mediate early IE-1 antigen that cover a wide range of human
leukocyte antigen (HLA) class I speciﬁcities [14]. The aim of
the present study was to determine the utility of monitoring
CMV-speciﬁc cell-mediated immunity to predict CMV
disease after discontinuation of prophylaxis in an international
cohort of D+/R− SOT recipients.
MATERIALS AND METHODS
Study Design and Participants
Participating transplant centers were identiﬁed through the
American Society of Transplantation Infectious Diseases Com-
munity of Practice. Adult SOT recipients were eligible if they
had a pretransplant D+/R− CMV serostatus and they were
scheduled to receive antiviral prophylaxis with either
ganciclovir or valganciclovir. Duration of prophylaxis was
allowed to be between 3 and 6 months. Immunosuppression
protocols were as per the center speciﬁc standard. We ob-
tained approval from institutional review boards before initia-
tion of enrollment at every site and all participants provided
written informed consent.
Enrollment was carried out between April 2008 and March
2011. Patients were followed longitudinally to assess the
development of CMV-speciﬁc cell-mediated immunity. Cell-
mediated immunity was measured at 3 time points in each
patient: at the time of prophylaxis discontinuation (ie, 3–6
months posttransplant), at 1 month postprophylaxis discon-
tinuation, and at 2 months postprophylaxis discontinuation.
Patients were followed for the development of CMV disease
for 12 months.
Procedures
Cell-mediated immunity was determined using the Quantifer-
on-CMV assay (Cellestis Ltd, a QIAGEN company) [15].
One-milliliter aliquots of whole blood were collected into 3
heparinized tubes. One tube contained a mix of 22 CMV
CD8+ T-cell synthetic epitopes (CMV tube); one tube con-
tained phytohemagglutinin (mitogen or positive control); and
the third tube contained only heparin (no antigen or negative
control). After collection, the 3 tubes were incubated overnight
at 37°C. Following incubation, the tubes were centrifuged and
plasma removed from each tube and placed in a plasma
storage container. These containers were then frozen at −70°C
(consistent with the manufacturer’s recommendations regard-
ing storage and processing), and IFN-γ measurement using an
enzyme-linked immunosorbent assay (ELISA) was subse-
quently performed in batch testing in 3 centers (Cleveland,
Ohio; Edmonton, Canada; and Leiden, the Netherlands). The
assay was performed in a blinded manner by one technician
in each center with experience in the use of the Quantiferon
platform.
According to the manufacturer, a cutoff of 0.2 IU/mL of
IFN-γ is used for deﬁning positivity of the assay [15].
However, based on previous data in D+/R− patients, the a
priori cut-point for deﬁning positivity was set at 0.1 IU/mL of
IFN-γ [16]. If the level was <0.1 IU/mL and the mitogen
control was positive (≥0.5 IU/mL), the test was considered to
be negative. Technically, if the level of IFN-γ in the CMV
antigen tube is <0.1 IU/mL and in the mitogen tube is <0.5
IU/mL, the result is indeterminate. For the purposes of the
analysis, negative and indeterminate results were also classiﬁed
together as being nonreactive.
The primary study endpoint was the incidence of CMV
disease within the 12 months after transplantation. We as-
sessed the value of the assay for prediction of protection
against CMV disease at the time of discontinuation of
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prophylaxis and at subsequent time points. The deﬁnition of
CMV disease was based on the criteria recommended by the
American Society of Transplantation for use in clinical trials [17].
In brief, CMV viremia was deﬁned by the detection of repli-
cating CMV in blood by either quantitative nucleic acid
testing or by the pp65 antigenemia assay. CMV disease was
deﬁned as evidence of CMV infection with compatible symp-
toms [17]. CMV disease was classiﬁed as tissue-invasive
disease if there was evidence of localized CMV infection in a
biopsy or another appropriate specimen, or as CMV syndrome
if there was no such evidence.
Statistical Analysis
We calculated the sample size on the basis of the primary end-
point of a lower incidence of CMV disease in patients with a
positive cell-mediated immune response. We assumed that the
percent of patients with a positive cell-mediated immune re-
sponse after prophylaxis was 30%. The overall CMV disease
rate was estimated to be approximately 25%: 5% in patients
with a positive cell-mediated immune response and 30% in
patients with a negative cell-mediated immune response. With
these assumptions, we estimated that 125 patients would be a
sufﬁcient sample size (α = .05, power = 0.80, 2-tailed). Baseline
characteristics of the patients were compared using the χ2 test
for categorical variables and the t test and the Mann-Whitney
test for continuous variables, when appropriate. The perfor-
mance of the assay for detecting protection from CMV disease
was assessed by calculation of the sensitivity, speciﬁcity, posi-
tive predictive value (PPV), and negative predictive value
(NPV). We calculated these parameters at the ﬁrst time point
of testing and at multiple time points. Any samples collected
after the occurrence of CMV disease were excluded for the
analysis of predictive value. The incidence of CMV disease ac-
cording to the result of the Quantiferon-CMV assay was cal-
culated using Kaplan-Meier curves. The cutoffs of IFN-γ levels
associated with the best sensitivity and speciﬁcity were ana-
lyzed by means of receiver operating characteristic (ROC)
curve analysis. We calculated ROC curves with IFN-γ levels
obtained in both CMV and mitogen tubes. Variables associat-
ed with an indeterminate result of the Quantiferon assay were
investigated by univariate analysis using the χ2 test. All analy-
ses were performed using PASW Statistics 20 software (IBM
Corporation), and a P value < .05 was considered to be statisti-
cally signiﬁcant.
RESULTS
Study Population
Overall, 127 patients were included in the study (Table 1).
Most patients were kidney (53.5%) or liver (21.2%) transplant
recipients. Immunosuppressive and prophylactic regimens are
summarized in Table 1. As per protocol, all patients received
antiviral prophylaxis either with valganciclovir or oral ganci-
clovir; 13.4% of the patients received intravenous ganciclovir
immediately posttransplant before switching to an oral agent.
Median duration of antiviral therapy was 98 days (interquar-
tile range [IQR], 92–178 days).
During the ﬁrst year after transplant, 50 of 127 (39.3%) pa-
tients developed CMV viremia, and 28 of 127 (22.0%) patients
developed CMV disease, at a median of 181 and 209 days
posttransplant, respectively. Twenty-two patients had CMV
viral syndrome and 6 patients had CMV tissue-invasive
disease. No episode of CMV disease was observed while pa-
tients were on prophylaxis. No differences in terms of organ
transplanted, immunosuppression, or antiviral prophylaxis
were observed between patients with and without CMV
disease.
Cell-Mediated Immunity
The Quantiferon-CMV assay was performed at all 3 time
points in 90 patients (70.8%), at 2 time points in 23 patients
(18.1%), and at 1 time point in 12 patients (9.4%). In 2 pa-
tients, the Quantiferon-CMV assay was not performed, and
therefore these 2 patients were excluded from the analysis
(Figure 1). As CMV disease induces a subsequent cell-mediated
response, the result of the assays performed after development
of CMV disease (n = 24) were not considered for the purpose
of our analysis (ie, prediction of subsequent CMV disease). Of
note, 1 patient developed CMV disease before the ﬁrst assay
was performed and was excluded from the analysis. At the
ﬁrst time-point testing, the Quantiferon-CMV assay was posi-
tive in 15 of 124 patients (12.1%), and nonreactive in 109 pa-
tients (87.9%; negative in 80 patients [64.5%] and
indeterminate [negative for both mitogen and CMV antigen
tube] in 29 patients [23.3%]) (Table 2). Subsequently, using
any of the 3 time points of testing, the Quantiferon-CMV
assay was positive in 31 of 124 patients (25%), and nonreactive
in 93 (75%) patients (negative in 81 patients [65.3%] and
indeterminate in 12 patients [9.7%]).
Predictive Value of Cell-Mediated Immunity
When analyzing the incidence of CMV disease according to
the results of the Quantiferon-CMV assay at multiple time
points, patients with a positive result of the assay had a lower
subsequent incidence of CMV disease (6.4%) than patients
with a negative (22.2%) and an indeterminate (58.3%) result
(P < .001; Figure 2A). When classifying both negative and in-
determinate results as nonreactive, the incidence of subse-
quent CMV disease was 6.4% vs 26.8% (P = .02; Figure 2B).
The performance of the assay for predicting protection against
CMV disease is shown in Table 3. Of note, sensitivity of the
assay was low (0.14; 95% conﬁdence interval [CI], .08–.23)
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when using the result of the ﬁrst assay, but increased using
multiple time points of testing (0.30; 95% CI, .21–.40). The
positive predictive value of the assay (ie, protection against
CMV disease in patients with a positive result of the assay)
remained high irrespective of the time point used. Incidence
of CMV viremia (either asymptomatic or in patients with
CMV disease) was not different in patients with a positive or
negative result of the Quantiferon-CMV assay but was in-
creased in patients with an indeterminate result (36%, 31.7%,
and 72.7% respectively; P = .013).
We compared IFN-γ levels of the CMV tube and the
mitogen tube in patients with and without CMV disease
(Figure 3). There was a trend toward higher IFN-γ levels
in patients without CMV disease in both the CMV and
mitogen tubes. For the CMV tube, median IFN-γ levels were
0.02 IU/mL (IQR, 0–0.16) in patients without CMV disease
and 0.005 IU/mL (IQR, 0–0.05) in patients with subsequent
CMV disease (P = .06). For the mitogen tube, median IFN-γ
levels were 9.65 IU/mL (IQR, 3.63–9.90) in patients without
CMV disease and 1.17 IU/mL (IQR, 0.34–9.95) in patients
with subsequent CMV disease (P = .06). Based on ROC curve
analysis, levels of ≥0.08 IU/mL of IFN-γ in the CMV tube
have a 32% sensitivity and 93% speciﬁcity for subsequent
protection for CMV disease. In the mitogen tube, levels of
≥2.2 IU/mL of IFN-γ have an 83% sensitivity and a 59%
speciﬁcity.
As patients with an indeterminate result of the Quantifer-
on-CMV assay had the highest incidence of CMV disease, we
looked for variables associated with an indeterminate result.
Patients who had received thymoglobulin for induction had a
higher rate of indeterminate results (9/47 [19.1%] vs 3/80
[3.7%]; P = .009). Patients on prednisone had a lower rate of
Table 1. Baseline Characteristics of the Patients Included in the Study
Total (N = 127) CMV Disease (n = 28) No CMV Disease (n = 99) P Value
Age, y, mean (SD) 50.0 (12.9) 51.4 (13.9) 49.6 (12.8) .66
Sex, M/F, No. 87/40 18/10 69/30 .58
Type of transplant .09
Kidney 68 (53.5%) 11 (39.3%) 57 (57.6%)
Kidney-pancreas 10 (7.8%) 2 (7.1%) 8 (8.1%)
Liver 27 (21.2%) 7 (25.0%) 20 (20.2%)
Lung 14 (11.0%) 5 (17.8%) 9 (9.1%)
Heart 4 (3.1%) 1 (3.6%) 3 (3.0%)
Othera 4 (3.1%) 2 (7.1%) 2 (2.0%)
Antiviral prophylaxisb
Intravenous ganciclovir 17 (13.4%) 3 (10.7%) 14 (14.1%) .57
Valganciclovir 122 (96.1%) 28 (100%) 94 (94.9%) .22
Oral ganciclovir 9 (7.1%) 2 (7.1%) 7 (7.1%) .99
Duration of prophylaxis, d, median (IQR) 98 (92–178) 124 (98–180) 98 (91–178) .2
Induction therapy .31
None 17 (13.4%) 4 (14.3%) 13 (13.1%)
Basiliximab 60 (47.2%) 10 (35.7%) 50 (50.5%)
Thymoglobulin 47 (37.0%) 14 (50.0%) 33 (33.3%)
Alemtuzumab 3 (2.4%) 0 (0%) 3 (3.0%)
Maintenance
Steroids 101 (79.5%) 23 (82.1%) 78 (78.8%) .7
Tacrolimus 113 (89.0%) 24 (85.7%) 89 (90.0%) .53
Cyclosporin 9 (7.1%) 4 (14.3%) 5 (5.0%) .1
MMF/MPA 103 (81.1%) 22 (78.6%) 81 (82.0%) .7
Azathioprine 7 (5.5%) 1 (3.6%) 6 (6.1%) .57
mTOR inhibitors 8 (6.3%) 3 (10.7%) 5 (5.0%) .3
Other 3 (2.4%) 1 (3.6%) 2 (2.0%) .63
Data are No. (%) unless otherwise specified.
Abbreviations: CMV, cytomegalovirus; IQR, interquartile range; MMF, mycophenolate mofetil; MPA, mycophenolic acid; mTOR, mammalian target of rapamycin.
a Two small bowel and 2 kidney and liver transplant recipients.
b Seventeen patients received initial intravenous ganciclovir prophylaxis; 4 patients received both valganciclovir and oral ganciclovir.
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indeterminate results (6/95 [6.3%] vs 6/20 [30%]; P = .006).
No other immunosuppressive drug inﬂuenced the response of
the Quantiferon-CMV assay.
DISCUSSION
In this multicenter study, we evaluated the predictive value of
CMV cell-mediated immunity testing using the Quantiferon-
CMV assay in a common clinical setting posttransplant:
predicting the development of CMV disease in high-risk
D+/R− patients after discontinuation of antiviral prophylaxis.
Patients with a positive Quantiferon-CMV result had a signiﬁ-
cantly lower incidence of subsequent CMV disease; patients
with a negative assay had an intermediate risk, and those with
an indeterminate result had a high risk. Therefore this test
would likely be useful in the clinical setting to stratify the risk
of CMV disease after discontinuation of prophylaxis. Given
the costs and potential toxicity of antiviral drugs, the assay
may help guide the duration of prophylaxis; once cell-mediated
immunity is detected, the antiviral drug could likely be safely
discontinued. Patients with a negative assay and especially
those with an indeterminate result would likely beneﬁt from
either more prolonged prophylaxis or closer monitoring.
The clinical experience with the use of the Quantiferon-
CMV assay to predict the development of CMV disease after
transplant is limited (reviewed in [14]). This is the ﬁrst study
to evaluate the predictive clinical utility of this assay in a large
cohort of exclusively D+/R− SOT recipients, who are at the
highest risk for the development of late-onset CMV disease.
We observed that 24% of patients developed a cell-mediated
immunity against CMV in the weeks following the discontinu-
ation of prophylaxis. In a previous single-center study that
included various serogroups of transplant recipients (including
35 D+/R− patients), patients with a detectable IFN-γ response
subsequently had a lower incidence of CMV disease as com-
pared to patients with a negative response (5.3% vs 22.9%;
P = .038) [16]. In D+/R− patients, 26.8% had a detectable cell-
mediated response at the time of discontinuation of prophy-
laxis; these patients had a trend toward lower incidence of
CMV disease (10% vs 40% in patients with a nonreactive
result). Likewise, in a recent study involving 67 lung transplant
recipients [18], patients with a positive Quantiferon-CMV
assay had lower incidence of subsequent CMV viremia (25%
vs 72% in patients with a negative result), and all 4 patients
who eventually developed CMV disease had a previous unde-
tectable cell-mediated immune response [18]. One of the limi-
tations of the Quantiferon assay in transplant patients appears
to be a low sensitivity, and so even lower cutoffs for deﬁning a
positive response may be appropriate [19, 20]. For example,
with a cutoff of 0.08 UI/mL of IFN-γ, we showed a slightly
higher sensitivity without losing speciﬁcity. However, the
results of our study are only applicable to D+/R− patients. Test
performance including sensitivity and predictive value may be
different in seropositive patients.
In our study, patients at the highest risk for the develop-
ment of late-onset CMV disease were those with an indetermi-
nate Quantiferon-CMV assay result in which both mitogen
and CMV antigen responses are absent. This likely reﬂects a
high net state of immunosuppression. Patients who had re-
ceived thymoglobulin, a polyclonal depleting antibody against
T cells, had higher rates of indeterminate results. The inci-
dence of indeterminate results decreased with subsequent
testing, and it was similar to that reported in previous studies
(ranging from approximately 20% to 30%) [18, 19, 21–23].
Therefore, patients with indeterminate results of the
Figure 1. Flow diagram of the study. Abbreviation: CMV,
cytomegalovirus.
Table 2. Results of the Quantiferon-Cytomegalovirus Assay at
Each Time Point
First Sample
(n = 124)
Second Sample
(n = 107)
Third Sample
(n = 73)
Positive 15 (12.1%) 21 (19.6%) 19 (26.0%)
Negative 80 (64.5%) 64 (59.8%) 43 (58.9%)
Indeterminate 29 (23.3%) 22 (20.6%) 11 (15.1%)
Samples collected after the development of CMV disease were excluded.
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Quantiferon-CMV assay may beneﬁt from a reduction of im-
munosuppression or an extension of antiviral prophylaxis
until immunosuppression reduction can safely occur.
In addition to the Quantiferon-CMV assay, several other
assays are available to assess CMV-speciﬁc cell-mediated
immune responses. These include the enzyme-linked immu-
nosorbent spot (ELISPOT) assay, major histocompatibility
complex peptide multimers, and intracellular cytokine staining
(ICS) by ﬂow cytometry [10]. Although none of these assays
can be considered the “gold standard” for the detection of
CMV-speciﬁc cell-mediated immunity, they are widely used in
research laboratories. Comparison between assays has been as-
sessed in a limited number of studies. The sensitivity of the
Quantiferon-CMV and of the ELISPOT to detect a cell-medi-
ated immune response was equivalent in a study involving 10
healthy seropositive volunteers [15]. In hematopoietic stem-
cell transplant recipients, the Quantiferon-CMV assay was
compared to an ICS assay [19]. With a cutoff for positivity of
0.2 UI/mL of IFN-γ for the Quantiferon-CMV test, concor-
dance between assays was 69% (κ value = 0.69). However,
using the ICS method as reference, the Quantiferon-CMV
assay detected a cell-mediated response in only 76% of cases.
The Quantiferon-CMV assay is HLA restricted, so some rare
HLA haplotypes may not be represented in the assay (<2%
of the population) [14]. Also, the assay primarily detects a
CD8+ T-cell response, but not a CD4+ T-cell response. Of
note, in the study by Clari and colleagues, the Quantiferon-
CMV assay appropriately correlated with polyfunctional
(both antiviral and cytotoxic) CMV-speciﬁc CD8+ T-cell
responses [19].
Figure 2. Kaplan-Meier curves of the incidence of cytomegalovirus (CMV) disease according to the result of the Quantiferon-CMV assay. A, Positive
vs negative vs indeterminate result of the assay (log-rank test, P < .001). B, Positive vs nonreactive result of the assay (log-rank test, P = .024). Abbrevi-
ation: CMV, cytomegalovirus.
Table 3. Sensitivity, Speciﬁcity, and Positive and Negative Predictive Values of the Quantiferon-Cytomegalovirus (CMV) Assay for
Detecting Protection Against CMV Disease
Patients With CMV Disease
Sensitivity
(95% CI)
Specificity
(95% CI)
Positive Predictive Value
(95% CI)
Negative Predictive
Value (95% CI)
First time-point Positive QF assay: 1/15 (6.7%) .14 (.08–.23) .96 (.81–.99) .93 (.68–.99) .24 (.16–.33)
Nonreactive QF assay: 26/109 (23.8%)
Any time-point Positive QF assay: 2/31 (6.4%) .30 (.21–.40) .93 (.76–.99) .93 (.78–.99) .27 (.18–.37)
Nonreactive QF assay: 25/93 (26.8%)
Abbreviations: CI, confidence interval; CMV, cytomegalovirus; QF, Quantiferon.
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Some limitations of our study need to be highlighted. First,
several patients developed a detectable cell-mediated response
only after subsequent testing in the 2 months following the
discontinuation of prophylaxis. While multiple time point
testing may improve the performance of the test, it may be
logistically difﬁcult to implement. Second, the method used to
detect CMV viremia was dependent on the center-speciﬁc lab-
oratory and included either quantitative nucleic acid testing or
pp65 antigenemia testing. However, both these methods are
recognized as appropriate for the diagnosis of CMV viremia
according to current guidelines [1, 2]. In addition, we included
only clinically symptomatic CMV disease, a stronger clinical
endpoint, as the primary endpoint of the study. Finally, sub-
stantial heterogeneity existed in our study population (type of
transplant, immunosuppression). However, all patients were
D+/R−, which is the most important and consistent risk factor
for CMV disease. This is one of the main strengths of our
study in addition to the international recruitment reﬂecting
current practices for CMV prevention around the world, and
the use of an assay that can be easily implemented in the ma-
jority of transplant centers.
In conclusion, we showed that in high-risk D+/R− SOT re-
cipients, assessment of cell-mediated immunity using the
Quantiferon-CMV assay has clinical utility for the prediction
of CMV disease. In those with a positive assay, the subsequent
incidence of CMV disease was low and those with either nega-
tive or indeterminate results had a higher incidence of CMV
disease. The Quantiferon-CMV assay may appropriately strati-
fy D+/R− SOT recipients according to their individual risk for
the development of CMV disease.
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